

Supplementary File

Recent Advances in Small Peptides of Marine Origin in Cancer Therapy

Qi-Ting Zhang¹, Ze-Dong Liu², Ze Wang², Tao Wang¹, Nan Wang³, Ning Wang^{1,*}, Bin Zhang^{2,*} and Yu-Fen Zhao¹

¹ Institute of Drug Discovery Technology, Ningbo University, Ningbo, Zhejiang, 315211, PR China

² Li Dak Sum Yip Yio Chin Kenneth Li Marine Biopharmaceutical Research Center, Department of Marine Pharmacy, College of Food and Pharmaceutical Sciences, Ningbo University, Ningbo, Zhejiang, 315800, PR China

³ Shenzhen Kivita Innovative Drug Discovery Institute, Shenzhen, Guangdong, 518057, PR China

* Correspondence: wangning2@nbu.edu.cn (N.W.); zhangbin1@nbu.edu.cn (B.Z.)

Table S1. Clinical information on Marine small peptide drugs

| Compound | Condition or disease | ClinicalTrials.gov Identifier: | Clinical Trial | Status | Study Completion Date |
|----------------------------|--|--------------------------------|-----------------|------------|-----------------------|
| E7974 | Advanced Solid Tumors | NCT00165802 | Phase I | Completed. | January 2009 |
| | Solid Malignancies | NCT00130169 | Phase I | Completed. | August 2009 |
| | Solid Malignancies | NCT00121732 | Phase I | Completed. | October 2009 |
| HTI-286 (Taltobulin) | Advanced solid tumours [1] | — ^a | phase I | Completed. | 2002 |
| Dolastatin 10 (NSC#376128) | Metastatic Prostate Cancer | NCT00003626 | Phase II | Completed. | May 2000 |
| | Recurrent or Metastatic Soft Tissue Sarcoma | NCT00003778 | Phase II | Completed. | July 2000 |
| | Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia | NCT00003693 | Phase I | Completed. | October 30, 2001 |
| | Metastatic Pancreatic Cancer | NCT00003677 | Phase II | Completed. | January 2002 |
| | Indolent Lymphoma, Waldenstrom's Macroglobulinemia, or Chronic Lymphocytic Leukemia | NCT00005579 | Phase II | Completed. | February 2003 |
| | Metastatic or Recurrent Liver, Bile Duct or Gallbladder Cancer | NCT00003557 | Phase II | Completed. | August 2003 |
| | Advanced Kidney Cancer | NCT00003914 | Phase II | Completed. | May 2009 |
| TZT-1027 | Progressive Locally Advanced or Metastatic Non-Small Cell Lung Cancer | NCT00061854 | Phase II | Completed. | May 2005 |
| | Advanced or Metastatic Soft Tissue Sarcoma | NCT00064220 | Phase II | Completed. | December 2005 |
| ILX-651 (Tasidotin) | Locally Advanced or Metastatic Non-Small Cell, Lung Carcinoma Small Cell, Lung Carcinoma | NCT00078455 | Phase II | Completed. | August 2005 |

| | | | | | |
|--|--|-------------|-----------------------------|-------------------------|--------------------|
| | Hormone-Refractory Prostate Cancer Previously Treated with Docetaxel | NCT00082134 | Phase II | Completed. | December 2005 |
| | Inoperable Locally Advanced or Metastatic Melanoma | NCT00068211 | Phase II | Completed. | January 2006 |
| Cematodin (LU103793) | Refractory Metastatic Solid Tumors [2] | -a | Phase I | Completed. | 1996 |
| Glembatumumab vedotin (CDX-011) | Unresectable Stage III or Stage IV Melanoma | NCT00412828 | Phase I Phase II | Completed. | May 2011 |
| | Locally Advanced or Metastatic Breast Cancer | NCT00704158 | Phase I Phase II | Completed. | June 2011 |
| | Advanced GPNMB-expressing Breast Cancer | NCT01156753 | Phase II | Completed. | November 2012 |
| | Recurrent or Refractory Osteosarcoma | NCT02487979 | Phase II | Completed. | June 30, 2017 |
| | Metastatic or Locally Recurrent Uveal Melanoma | NCT02363283 | Phase II | Completed. | July 2, 2018 |
| | Metastatic, gpNMB Over-Expressing Triple Negative Breast Cancer | NCT01997333 | Phase II | Completed. | August 7, 2018 |
| | gpNMB-Expressing, Advanced or Metastatic SCC of the Lung | NCT02713828 | Phase I Phase II | Terminated. Has Results | September 26, 2018 |
| | Immunotherapies in Patients with Advanced Melanoma | NCT02302339 | Phase II | Terminated. Has Results | October 3, 2018 |
| Brentuximab vedotin (SGN-35, Monomethyl Auristatin E, Adcetris.) | A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study | NCT00947856 | Phase II | Completed. | March 2013 |
| | Relapsed or Refractory Hodgkin Lymphoma | NCT00337194 | Phase II | Completed. | October 2014 |
| | CD30-positive Nonlymphomatous Malignancies | NCT01461538 | Phase II | Completed. | December 2014 |
| | Hodgkin Lymphoma | NCT00848926 | Phase II | Completed. | May 2015 |
| | Relapsed or Refractory Non-Hodgkin | NCT01421667 | Phase II | Completed. | June 2015 |

| | | | | | |
|--|--|-------------|-----------------------------|------------|-------------------|
| | Lymphoma | | | | |
| | Mycosis Fungoides With Variable CD30 Expression Level | NCT01396070 | Phase II | Completed. | May 2016 |
| | Systemic Anaplastic Large Cell Lymphoma | NCT00866047 | Phase II | Completed. | June 2016 |
| | Relapsed or Refractory PMLBCL (FIL_SGN01) | NCT02423291 | Phase II | Completed. | July 2016 |
| | Hodgkin Lymphoma | NCT01393717 | Phase II | Completed. | February 1, 2017 |
| | Advanced Systemic Mastocytosis or Mast Cell Leukemia | NCT01807598 | Phase II | Completed. | September 2017 |
| | Limited-stage Hodgkin Lymphoma | NCT01534078 | Phase II | Completed. | January 2018 |
| | Hodgkin Lymphoma | NCT01874054 | Phase I Phase II | Completed. | February 20, 2018 |
| | Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma | NCT01492088 | Phase I Phase II | Completed. | April 12, 2018 |
| | CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study) (ALCANZA) | NCT01578499 | Phase III | Completed. | July 6, 2018 |
| | Non-bulky Limited Stage Hodgkin Lymphoma | NCT02505269 | Phase II | Completed. | June 2019 |
| | Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL) | NCT02939014 | Phase II | Completed | February 3, 2020 |
| | High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial) | NCT01100502 | Phase III | Completed. | April 27, 2020 |
| | CD30+ PMBL, Diffuse Large B-Cell, and Grey Zone Lymphoma Patients | NCT01994850 | Phase I Phase II | Completed. | January 5, 2021 |

| | | | | | |
|----------------------------------|---|-------------|-----------------------------|-------------------------|---------------|
| | Relapsed or Refractory Hodgkin Lymphoma | NCT01990534 | Phase IV | Completed. | June 10, 2021 |
| Didemnin B (NSC 325319) | Advanced Epithelial Ovarian Cancer [3]. | –a | Phase II | Completed. | 1992 |
| | Metastatic Breast Cancer [4]. | –a | Phase I | Completed. | 1992 |
| | Myeloma. A Cancer and Leukemia [5]. | –a | phase II | Completed. | 1994 |
| | Advanced Malignant Melanoma [6] | –a | phase II | Completed | 1998 |
| | Central Nervous System Tumors [7] | –a | Phase II | Completed. | 1999 |
| | Recurrent or Refractory Anaplastic Astrocytoma or Glioblastoma Multiforme [8] | –a | Phase II | Completed. | 1999 |
| | Previously Treated Non-Hodgkin's lymphoma [9] | –a | Phase II | Completed | 2000 |
| Aplidine (Dehydroididemnin B) | Advanced Prostate Cancer | NCT00780975 | Phase II | Terminated. Has Results | March 2008 |
| | Relapsing or Refractory Multiple Myeloma | NCT00229203 | Phase II | Completed. | August 2008 |
| | Relapsed/Refractory Leukemia | NCT00780143 | Phase I Phase II | Completed. | June 2009 |
| | Relapsed/Refractory Aggressive Non Hodgkin Lymphoma | NCT00884286 | Phase II | Terminated. Has Results | June 2010 |
| | Primary Myelofibrosis | NCT01149681 | Phase II | Terminated. Has Results | February 2011 |
| | Advanced Solid Tumors or Lymphomas | NCT00788099 | Phase I | Completed. | June 2011 |
| | Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS) | NCT01876043 | Phase II | Terminated. Has Results | April 2015 |
| | Relapsed/Refractory Myeloma (ADMYRE) | NCT01102426 | Phase III | Completed. | November 2017 |
| | Multiple Myeloma | NCT02100657 | Phase I | Completed. | June 2018 |
| | Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide | NCT03117361 | Phase II | Completed. | July 2018 |

| | | | | | |
|------------|---|----------------|-----------------------------|-------------------------|----------------|
| | Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma | NCT03070964 | Phase II | Terminated. Has Results | July 2018 |
| | COVID-19 (APLICOV-PC) | NCT04382066 | Phase I | Completed. | December 2020 |
| Plinabulin | Advanced Solid Tumors or Lymphoma | NCT00322608 | Phase I | Completed. | December 2009 |
| | Advanced Non-Small Cell Lung Cancer | NCT00630110 | Phase I Phase II | Completed. | June 2011 |
| | Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2 | NCT04345900 | Phase II | Completed. | April 2018 |
| | Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer | NCT02846792 | Phase I Phase II | Terminated. Has Results | August 2018 |
| | TAC Induced Neutropenia | NCT04227990 | Phase II | Completed. | January 2019 |
| | Advanced NSCLC (DUBLIN-3) | NCT02504489 | Phase III | Recruiting. | November 2020 |
| | Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3 (Protective-1) | NCT03102606 | Phase III | Active, not recruiting. | December 2020 |
| | Recurrent Small Cell Lung Cancer | NCT03575793 | Phase I Phase II | Recruiting. | September 2022 |
| | Metastatic Non-Small Cell Lung Cancer (NSCLC) | NCT02812667 | Phase I | Recruiting. | December 2022 |
| | Prevention of TAC Induced Neutropenia | NCT03294577 | Phase III | Active, not recruiting. | September 2025 |
| Halimide | Advanced, Metastatic Non-small Cell Lung Cancer [10] | - ^a | Phase II | Completed. | 2015 |
| LY355703 | Inhibits the Growth of Various Tumour Cells [11] | - ^a | Phase II | Completed. | 1998 |
| | Phase I and pharmacological Studies of the Cryptophycin Analogue LY355703 Administered [12] | - ^a | Phase I | Completed. | 2002 |

Notes: -^a Data not mentioned.

References

1. Ratain, M.J.; Undevia, S.; Janisch, L.; Roman, S.; Mayer, P.; Buckwalter, M.; Foss, D.; Hamilton, B.L.; Fischer, J.; Bukowski, R.M. Phase I and pharmacological study of HTI-286, a novel antimicrotubule agent: correlation of neutropenia with time above threshold plasma concentration. *Proc Am Soc Clin Oncol*, **2003**, *129*, abstract 516.
2. Poruchynsky, M.S.; Kim, J.H.; Nogales, E.; Annable, T.; Loganzo, F.; Greenberger, L.M.; Sackett, D.L.; Fojo, T. Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha- or beta-tubulin and increased microtubule stability. *Biochemistry* **2004**, *43*, 13944-13954, doi:10.1021/bi049300+.
3. Cain, J.M.; Liu, P.Y.; Alberts, D.E.; Gallion, H.H.; Laufman, L.; O'Sullivan, J.; Weiss, G.; Bickers, J.N. Phase II trial of didemnin-B in advanced epithelial ovarian cancer. A Southwest Oncology Group study. *Invest New Drugs* **1992**, *10*, 23-24, doi:10.1007/bf01275473.
4. Benvenuto, J.A.; Newman, R.A.; Bignami, G.S.; Raybould, T.J.; Raber, M.N.; Esparza, L.; Walters, R.S. Phase II clinical and pharmacological study of didemnin B in patients with metastatic breast cancer. *Invest New Drugs* **1992**, *10*, 113-117, doi:10.1007/bf00873128.
5. Weiss, R.B.; Peterson, B.L.; Allen, S.L.; Browning, S.M.; Duggan, D.B.; Schiffer, C.A. A phase II trial of didemnin B in myeloma. A cancer and leukemia group B (CALGB) study. *Invest. New Drugs* **1994**, *12*, 41-43, doi:10.1007/bf00873234.
6. Hochster, H.; Oratz, R.; Ettinger, D.S.; Borden, E. A phase II study of Didemnin B (NSC 325319) in advanced malignant melanoma: an eastern cooperative oncology group study (PB687). *Invest New Drugs* **1998**, *16*, 259-263, doi:10.1023/a:1006110431250.
7. Taylor, S.A.; Giroux, D.J.; Jaeckle, K.A.; Panella, T.J.; Dakhil, S.R.; Schold, S.C. Phase II study of Didemnin B in central nervous system tumors: a southwest oncology group study. *Invest New Drugs* **1998**, *16*, 331-332, doi:10.1023/a:1006273214056.
8. Mittelman, A.; Chun, H.G.; Puccio, C.; Coombe, N.; Lansen, T.; Ahmed, T. Phase II clinical trial of didemnin B in patients with recurrent or refractory anaplastic astrocytoma or glioblastoma multiforme (NSC 325319). *Invest New Drugs* **1999**, *17*, 179-182, doi:10.1023/a:1006379402114.
9. Kucuk, O.; Young, M.L.; Habermann, T.M.; Wolf, B.C.; Jimeno, J.; Cassileth, P.A. Phase II trail of didemnin B in previously treated non-Hodgkin's lymphoma: an eastern cooperative oncology group (ECOG) study. *Am J Clin Oncol* **2000**, *23*, 273-277, doi:10.1097/00000421-200006000-00013.
10. Millward, M.; Mainwaring, P.; Mita, A.; Federico, K.; Lloyd, G.K.; Reddinger, N.; Nawrocki, S.; Mita, M.; Spear, M.A. Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel. *Invest. New Drugs* **2012**, *30*, 1065-1073, doi:10.1007/s10637-011-9642-4.
11. Mooberry, S.L.; Busquets, L.; Tien, G. Induction of apoptosis by cryptophycin 1, a new antimicrotubule agent. *Int. J. Cancer* **1997**, *73*, 440-448, doi:10.1002/(sici)1097-0215(19971104)73:3<440::aid-ijc20>3.0.co;2-f.

12. Sessa, C.; Weigang-Köhler, K.; Pagani, O.; Greim, G.; Mora, O.; De Pas, T.; Burgess, M.; Weimer, I.; Johnson, R. Phase I and pharmacological studies of the cryptophycin analogue LY355703 administered on a single intermittent or weekly schedule. *Eur. J. Cancer* **2002**, *38*, 2388-2396, doi:10.1016/s0959-8049(02)00489-6.